Kura Oncology FY2029 EPS Cut by Brookline Capital Markets

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at Brookline Capital Markets lowered their FY2029 earnings estimates for shares of Kura Oncology in a report released on Wednesday, August 12th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings per share of $5.70 for the year, down from their prior estimate of $6.01. The consensus estimate for Kura Oncology’s current full-year earnings is ($3.45) per share.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. The company had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 169.73%.

Several other equities research analysts also recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, June 15th. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Oppenheimer set a $24.00 price target on shares of Kura Oncology in a report on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $25.62.

Kura Oncology Stock Performance

NASDAQ KURA opened at $10.09 on Friday. The firm’s fifty day moving average price is $10.17 and its two-hundred day moving average price is $9.32. The stock has a market cap of $895.69 million, a PE ratio of -2.99 and a beta of 0.38. Kura Oncology has a fifty-two week low of $6.35 and a fifty-two week high of $12.49. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new stake in Kura Oncology during the 2nd quarter worth about $115,286,000. Suvretta Capital Management LLC boosted its position in shares of Kura Oncology by 5.7% during the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after purchasing an additional 459,422 shares in the last quarter. Vanguard Group Inc. grew its stake in Kura Oncology by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock worth $57,224,000 after purchasing an additional 39,105 shares during the period. Armistice Capital LLC grew its stake in Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after purchasing an additional 264,000 shares during the period. Finally, State Street Corp increased its holdings in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares in the last quarter.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.60% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.